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Summary Immunohistochemically detectable p53 protein using a polyclonal antibody (CM-I) was studied in
42 carcinomas of which 11 were grade I, 22 grade II and nine grade III carcinomas. Additionally 14 urothelial
dysplasias were studied. In 11 of these a diagnosis of transitional cell carcinoma was established before and in
one after the dysplasia diagnosis. Twenty-one out of 42 (50%) cases of transitional cell carcinoma were
positive for the p53 protein. Eleven out of 14 (78%) dysplasias and 10/12 (83%) related carcinomas were p53
positive. One out of 11 grade 1 (9%), 12/22 grade 11(55%) and 8/9 grade III (89%) tumours showed positivity
for p53. There were significantly more p53 positive cases in grade II-III tumours than in grade I tumours
(P = 0.004). There were significantly more p53 positive cases in stage T2-T4 tumours than in stage T, tumours
(P = 0.035). In only one case among the 11 dysplastic lesions following the treatment of a carcinoma the
dysplastic lesion was p53 negative while the preceding carcinoma was p53 positive. All dysplasias and 28
carcinomas were also immunostained for laminin and type IV collagen to evaluate the continuity of basement
membranes (BMs). Clearly disrupted BMs were observed only in grade III carcinomas. These cases showed the
most p53 immunopositivity. The results show a strong association of p53 staining between dysplasias and
transitional cell carcinomas of the urinary bladder indicating that these lesions might share similar p53
changes. The correlation to grade, clinical stage and to disrupted BM suggests that p53 mutations may be
associated with the evolution of aggressive growth characteristics in transitional cell carcinomas or, alterna-
tively, that p53 positive tumours of a more aggressive type from the start. Whether p53 staining can be used as
an adjunct in the assessment and follow-up of epithelial changes of patients treated for a p53 positive bladder
carcinoma deserves to be studied.
The p53 gene encodes a cellular phosphoprotein the function
of which is not fully clarified. There are indications that it
takes part in the regulation of cell proliferation (Deppert et
al., 1990; Milner, 1991; Bischoff et al., 1990; Lane & Benchi-
mol, 1990; Mercer et al., 1984; Steinmeyer et al., 1990) or
acts as a transcriptional factor (Farmer et al., 1992). The
product of the gene has been shown to have tumour suppres-
sor properties (Finlay et al., 1989; Eliyahu et al., 1989).
Mutations of the p53 gene have been found in a wide variety
of human malignancies (Nigro et al., 1989; Hollstein et al.,
1991). Bladder carcinomas, which have been reported to
contain chromosomal alterations such as deletions of the
chromosomes 9, 11 and 17 (Olumi et al., 1990; Sidransky et
al., 1991), activation of the oncogenes ras and c-erbB-2 (San-
tos et al., 1982; Wright et al., 1991) and inactivation of the
retinoblastoma gene (Ishikawa et al., 1991), also contain
mutations of the p53 gene (Sidransky et al., 1991). Recently,
immunohistochemical reactivity for the p53 protein was
found in 54% of bladder carcinomas (Wright et al., 1991).
There is a considerable variation in the incidence of p53
mutations in different types of tumours (Hollstein et al.,
1991). Lung and colon carcinomas, for instance, harbour a
high rate of p53 mutations (Iggo et al., 1990; Chiba et al.,
1990; Purdie et al., 1991; Vogelstein, 1989), while the fre-
quency of p53 mutations is lower in endometrial and thyroid
carcinomas (Risinger et al., 1992; Wright et al., 1991). The
reasons for these differences are still unclear, but some recent
studies indicate that the aetiology of a tumour may deter-
mine, at least partly, the state of p53. p53 mutations can be
induced experimentally by chemical carcinogens (Halevy et
al., 1991). A typical mutational spectrum of p53 linked to
specific carcinogens suggests that p53 is one of the targets of
these chemicals (Hsu et al., 1990; Vahakangas et al., 1992).
Another unresolved question is the relation of p53 to the
development of a tumour. In some investigations mutations
of the p53 gene has been assumed to represent late events in
tumorigenesis (Mazards et al., 1991). Immunohistochemical
studies, however, show that changes in the p53 gene may
already be present in premalignant non-invasive lesions such
as dysplasias of oral (Gusterson et al., 1991) and bronchial
mucosa (Nuorva et al., 1993). The metaplastic epithelium of
an oesophageal Barrett's lesion in association with an oeso-
phageal adenocarcinoma has also been shown to contain p53
mutations (Casson et al., 1991). Such findings indicate that
p53 mutations may also occur early, at least in some types of
tumours.
To shed some light on these questions in bladder car-
cinoma we analysed p53 immunohistochemically using a
polyclonal antibody (CM-1) in 42 transitional cell carcinomas
and 14 dysplasias of the bladder epithelium. CM-1 is raised
against the wild type p53 protein but detects mainly the
mutated p53 protein due to the accumulation of the mutated
protein which has a longer half-life than the wild type (Midg-
ley et al., 1992; Bartkova et al., 1991). All 14 dysplasias and
28 carcinoma sections were also stained with polyclonal anti-
bodies to laminin and type IV collagen in order to visualise
the integrity of the basement membranes (BMs) and in this
way to relate the p53 status to the aggressiveness and
invasiveness of the tumour.
Materials and methods
Cases
Consecutive urothelial carcinomas and dysplasias were col-
lected from the files of the Department of Pathology, Oulu
University Central Hospital. All the tissue material used in
this investigation had been fixed in 10% neutral formalin and
embedded in paraffin. The material included both cystectomy
specimens (n = 12) and surgical biopsies (n = 46). The
tumour material consisted of 42 transitional cell carcinomas
including 11 grade I, 22 grade II and nine grade III car-
cinomas. All grade I and all but two grade II carcinomas
were papillary, while six grade III carcinomas were nonpapil-
lary and three papillary (see Tables I and III). The diagnosis
and the grades of the tumours were based on the WHO
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Table I Results of immunostaining with antibodies to p53 and BM proteins laminin and type IV
collagen in transitional cell carcinomas not associated with in situ lesions
Histology Clinical data
Invasion in stained Survival
Case pS3 BM histological section Stage Follow-up (months)
Grade I transitional cell carcinomas:
+ + + + - TaNOMO no recidives 24+
2 - + + + + - TINOMO recidives, LCT 62+
3 + ++++ - TINOMO recidives, LCT 107+
4 - + + + - TINOMO recidives, LCT 54+
5 - - TINOMO recidives, LCT 144+
6 - ++++ - T2NOMO recidives, LCT 36+
7 - + + + + - TaNOMO one recidive, LCT 67+
8 - + + + + - TaNOMO recidives, LCT 36-*
9 - - n n n
Grade II transitional cell carcinomas:
10 - + + + - TINOMO recidives, LCT 66+
11 - ++++ - T3NOMO recidives, RO 28+
12 - - TINOMO recidives, LCT 36-
13 - + + + - TINOMO recidives, LCT 42+
14 - ++++ - TaNOMO recidives, LCT 25+
15 + + + + + - T2NOMO RO 0.5-
16 - ++++ - T2NOMO one recidive, LCT 20-#
17 + + + + + - TaNOMO recidives, LCT 50-
18 - + + + - TaNOMO recidives, LCT 21 +
19 ++++ ++ + T2NOMO no recidives 4-#
20 - + + + + - TINOMO recidives, LCT 136+
21 - + + + + - TINOMO recidives, LCT 3-#
22 + ++++ - TINOMO recidives, LCT 87-#
23 - - T4NOMO progression, RT 11-
Grade III transitional cell carcinomas:
24 + + + + + T4NOMO progression, RT 78-
25 + + + + TINOMO recidives, BR 60+
26* + - + T3aNOMO RO 80-
27* + + + + - + T2NOMO RO 76+
28* - - + T4NOMO, progression, RT 26-
29* + + - + n n n
30* + + + - + T3NlMl progression, RT 12-
p53 immunoreactivity: -= negative; + = 1-5%, + + = 6-10%, + + + = 11-40%, + + + + =
more than 40% of nuclei positive. BM: -= lacking, + = mostly lacking, + + = defective in many
areas, + + + = defective in some areas, + + + + = intact. Invasion: - =absent, + = present.
Follow-up: LCT = local conservative treatment, RT= radiotherapy, BR = bladder resection, RO =
radical operation. Survival: + = alive, - = dead, # = died of other reasons than bladder carcinoma.
Other symbols: * = nonpapillary,arcinoma, n = information lacking.
Histological Classification of Urinary Bladder Tumours
(Mostofi et al., 1973). The dysplasias were diagnosed accord-
ing to Nagy et al. and graded into three grades (mild,
moderate, severe) (Nagy et al., 1982). In 12/14 dysplasias a
transitional cell carcinoma was found either before (n = 11)
or after (n = 1) the biopsy. From these cases carcinomas
temporarily closest to the dysplasias were also studied for
p53 immunoreactivity. The full case histories were re-eval-
uated from the medical charts of the patients. The UICC
TNM pathological staging system was used to assess the
disease progression at the time of the diagnosis and is pre-
sented in Tables I and III. The nature of the adjuvant
treatment for the bladder cancer prior to the diagnosis of
dysplasia is given in Table III.
Immunostaining with thep53 antibody
The immunostaining procedure was done according to Midg-
ley et al. (1992). One block of each tumour specimen was
studied. Five micrometer thick sections were cut from the
specimens and placed on slides coated with poly-L-lysine
solution (Sigma Chemicals, St Louis, MO, USA). The speci-
mens were then dewaxed in xylene and dehydrated in graded
alcohol. The endogenous peroxidase was blocked by immers-
ing the sections for 10min in 0.1% hydrogen peroxide in
absolute methanol. The non-specific binding was blocked by
incubating the slides in 20% foetal calf serum in phosphate
buffered saline (PBS) for 20 min.
In the immunostaining the ABC (avidin-biotin-complex)
method was used (Hsu et al., 1981). The sections were first
incubated overnight at 4°C with a primary polyclonal rabbit
p53 antibody CM-1 with a dilution of 1:1000. The CM-1
antibody has been prepared against human wild-type p53
protein in a recombinant bacterial system but mainly detects
the mutated protein according to the characterisation by
Midgley et al. (1992) and Bartkova et al. (1991). This was
followed by a secondary biotinylated anti-rabbit antibody
(dilution 1:400) and the avidin-biotin-complex (both from
Dakopatts, Copenhagen, Denmark). Careful rinses were done
with several changes of PBS between each stage of the proce-
dure. The colour was developed with diaminobenzidine
whereafter the sections were lightly counterstained with
haematoxylin and mounted in Eukitt (Kindler GmbH, Frei-
burg, Germany).
In each set of immunostainings a lung carcinoma case,
which was known to express p53 (Soini et al., 1992), was
used as a positive control. Negative controls for the immuno-
staining were carried out by substituting the primary anti-
body with non-immune rabbit serum.
Immunostaining with laminin and type IV collagen antibodies
The fragment P1 of laminin was purified from human
placenta (Risteli et al., 1981) and the 7S domain of type IV
collagen from human kidney (Risteli et al., 1980). Antisera
were raised in rabbits and specific antibodies were prepared
by immunoadsorption on the relevant antigen, coupled to
Sepharose 4B, after cross-adsorption with other immobilised
extracellular matrix proteins. In the immunostaining, the
ABC-method was used (Hsu et al., 1981) on sections cut
from formalin fixed and paraffin embedded specimens. Before
antigen-antibody reaction the endogenous peroxidase wasp53 IN URINARY BLADDER CANCER 1031
inactivated with 0.1% hydrogen peroxide in methanol, and
the sections were treated with 0.4% pepsin (Merck, Darm-
stadt, Germany) in 0.01 M HCI to enhance the availability of
antigenic determinants (Ekblom et al., 1982). For control
staining PBS and normal rabbit serum were used instead of
the primary antibody.
Analysis ofp53 immunoreactivity
The results were evaluated quantitatively and divided into
five groups (- =negative; + = 1-5% of nuclei positive;
+ + = 6-10% of nuclei positive; + + + = 11-40% of nuclei
positive; + + + + = more than 40% of nuclei positive).
Table II p53 immunoreactivity in relation to the grade of the
bladder carcinomasa
Bladder carcinomas (number of cases)
p53 Grade I Grade II Grade III Total
- 10 (91%) 10 (44%) 1 (11%) 20 (48%)
+ 1 (9%) 5 (23%) 2 (22%) 8 (19%)
+ + 0 (0%) 2 (9%) 1 (11%) 3 (7%)
+++ 0 (0%) 4 (18%) 2 (22%) 6 (14%)
*++++ 0 (0%) 1 (5%) 3(33%) 4 (10%)
Total 11 22 9 42
p53 immunoreactivity: - = negative, + = 1-5%,
+++=11-40%, ++++=more than 40% of
aAll studied carcinomas included.
++ =6-10%,
nuclei positive.
Statistical analysis
Fisher's exact probability test was used in the statistical
analysis of the data. Progression-free interval was defined as
the time from the date of diagnosis to the date of disease
progression. Progression was defined as worsening of the
histological grade of the tumour or other clinical progression.
Disease progression rates were calculated and the Kaplan-
Meier method (Simon, 1989) was used to derive the pro-
gression-free intervals in the two groups of patients defined
according to the results of the immunostaining of biopsies
(i.e. p53 negatives/p53 positives).
Results
p53 in transitional cell carcinomas
Twenty-one out of all the 42 transitional cell carcinomas
studied (50%) showed p53 positive nuclear staining (Figures
3a and 4a). However, in the material preceding the dysplastic
lesions (Table III) this percentage was 91% (10/11). One out
of the 11 (9%) grade I, 12 out of 22 grade II (55%) and eight
out of the nine (89%) grade III carcinomas were positive
(Table II). According to Fisher's exact probability test there
were significantly more p53 positive cases in grade II-III
tumours than in grade I tumours (P = 0.004). There were
also significantly more p53 positive tumours in grade III than
in grade I-II tumours (P = 0.033). The grade III tumours
also contained a higher number of positive cells than the
lower grade tumours (Table II). There were significantly
more p53 positive cases in stage T2-T4 tumours than in T,
tumours (P= 0.035 according to Fisher's exact probability
test). Seven out of eight nonpapillary tumours were p53
positive (88%) while 13 out of 34 papillary tumours (38%)
were p53 positive. The immunoreactivity was located in the
nuclei of the neoplastic cells. Occasionally, however, cyto-
plasmic positivity was also seen. Interestingly, some of the
mitotic tumour cells expressed cytoplasmic positivity. In
areas of infiltration the p53 positive neoplastic cells could
easily be discerned from the surrounding reactive cells. In
some biopsy samples, p53 positive cells which had detached
from the neoplastic epithelium could be seen (Figure la).
p53 in dysplasia ofthe transitional epithelium
Positivity for the p53 protein could be found in 11 out of 14
dysplasias (78%) (Table III). The immunoreactivity was
located in the cell nuclei in general; however, occasionally
intracytoplasmic reactivity was also seen. Immunoreactivity
was more frequently found in the basal areas of the epithe-
lium. In all but two cases a diagnosis of transitional cell
carcinoma had been established in previous or subsequent
biopsies (see Table III).
In most of the p53 positive cases of dysplasia the p53
immunoreactivity was sustained in the previous or subse-
quent carcinoma samples (Table III). In one case ofdysplasia
(case 34) with negative p53 staining, a p53 negative transi-
tional cell carcinoma was found. In another case with nega-
tive p53 staining (case 43) the carcinoma was p53 positive. In
case 32 there was no report of a transitional cell carcinoma,
but a rhabdomyosarcoma of the bladder was diagnosed in
the same year.
Laminin and type IV collagen immunoreactivity in dysplastic
lesions and carcinomas
A linear BM, positive for laminin and type IV collagen could
usually be found beneath the epithelium of the dysplastic
lesions (Figures lb and 2b) and the proliferating papillary
b
Figure 1 Immunoreactivity for p53 and type IV collagen in
severe dysplasia of the urothelial epithelium a, p53 is present in
the nuclei of the epithelial cells. Two detached p53 positive cells
are seen in the lumen. b, A neighbouring section stained for type
IV collagen, showing an intact BM beneath the epithelium
(Immunoperoxidase stain, a & b x 260).1032 Y. SOINI et al.
Table III Clinical history and p53 immunohistochemistry in dysplastic lesions of the urinary bladder
and corresponding carcinomas
Year and diagnosis
Treatment
preceding Survival Dysplasia
No p53 in carcinoma Clinical stage Follow-up dysplasia (months) p53 grade
Dysplasia without a carcinoma
31a + + S
32b _ m
Dysplasia before carcinoma
33 - GI TINOMO recidives NO 144+ + I
Dysplasia after treatment of carcinoma
34 - GI TINOMO recidives CT 120+ - s
35 + + + GII T3bNlM0 progressive CT + RT 84- + + + m
36 + + GII TINOMO recidives NO 72-# + m
37* + + GII T2NOMO progressive CT + RT 47- + m
38 + + + GII T3NOMO NO 57+ + + m
39* + + + GII T3NOMO progressive RT 15- + + s
40 + GII TINOMO recidives CT 78+ + m
41 + GII T4NOMO progressive NO 11- + m
42 + + + GII TINOMI progressive NO 28- + + + m
43 + + + + GIII T4NOMO progressive RT 44- -
44* + + + + GIII TINOMO progressive RT 30- + m
p53 immunoreactivity: - = negative, + = 1-5%, + + = 6-10%, + + + = 11-40%,
+ + + + = more than 40% of nuclei positive. Grades: GI, GII, GIII = grade 1, 2 or 3 of the
carcinoma. Grade of dysplasia (s = severe, m = moderate, I = mild). Survival: + = alive, - = dead,
= died of other reasons than bladder carcinoma. Treatment: CT = local chemotherapy (instillations),
RT = radiotherapy. Other symbols: * = nonpapillary carcinoma. aDysplasia of ureter, bThe patient had
a concurrent rhabdomyosarcoma of the bladder.
structures in grade I and II transitional cell carcinomas
(Figure 3b). In some cases, especially in carcinomas, the BM
was attenuated and focally deficient. In contrast, the BM was
frequently absent in grade III transitional cell carcinomas,
especially in invasive areas (data not shown). Granular intra-
cytoplasmic laminin immunoreactivity could be observed in
some of the tumour cells in nine tumours, seven out of which
represented grade III and two grade II transitional cell car-
cinomas (Figure 4b). No intracytoplasmic immunoreactivity
for type IV collagen could be observed in any of the car-
cinomas.
The BMs of the blood vessels, smooth muscle cells and
adipocytes stained positive for laminin and type IV collagen
in the bladder wall. An apparent increase in the number of
the blood vessels was seen beneath the dysplastic and neo-
plastic papillary epithelium (Figure 2b).
Seven of the p53 positive tumours showed areas of inva-
sion. Thus, the degree of p53 positivity was related to the
disruption of the BMs and the presence of invasion in the
tumours. Six out of these seven tumours exhibited con-
comitant intracytoplasmic laminin immunoreactivity (Figures
4a and 4b).
Correlation ofthep53 nuclear overexpression to the
progression ofbladder cancer
We defined two groups of patients according to the different
patterns of staining for p53 and compared the progression-
free intervals in these groups using the Kaplan-Meier analysis
(Figure 5). The rate of disease progression was higher in the
group of patiens showing positive staining for p53 when
compared to patients with negative p53 staining.
Discussion
We found a 50% frequency of p53 positivity in our bladder
carcinoma material. This concords with other investigations,
where mutations of the p53 gene and immunohistochemical
positivity for p53 protein have been found in 40-60% of
transitional cell carcinomas (Olumi et al., 1990; Sidransky et
al., 1991; Wright et al., 1991). In this study all tumours
associated with p53 positive dysplastic lesions were either of
grade II or III (see Table III). Furthermore, p53 positivity in
carcinoma material was clearly concentrated in tumours of
higher grade and invasion (see Table I). Since generally in
a
b
Figure 2 Immunoreactivity for p53 and type IV collagen in
moderate dysplasia of the urinary bladder. a, The nuclei of the
cells stain strongly for p53. b, A neighbouring section stained for
type IV collagen. An intact BM is seen beneath the epithelium.
Note also the increased vascularity beneath the epithelium,
revealed by the type IV collagen stain (Immunoperoxidase stain,
a & b x 260).p53 IN URINARY BLADDER CANCER 1033
a
b
Figure 3 p53 and type IV collagen immunoreactivity in a grade
II transitional cell carcinoma. a, Strong staining for p53 is seen in
the nuclei of the neoplastic cells. b, A type IV collagen positive
BM can be seen beneath the papillary fronds of the tumour
(Immunoperoxidase stain, a & b x 260).
10 20 30 40 50 60 70
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Figure 5 Kaplan-Meier analysis of the progression-free survival
in p53 positive and p53 negative cases showing a higher rate of
urinary bladder carcinoma progression in patients expressing p53
positivity in the tumour compared to patients with negative p53
staining in the tumour.
normal cells p53 protein is undetectable by immunohisto-
chemistry (Bartek et al., 1990; Iggo et al., 1990; Porter et al.,
1992; Barnes et al., 1992), these results suggest that events
leading to the accumulation of p53 protein play a part in the
Figure 4 Immunoreactivity for p53 and laminin in a grade III
transitional cell carcinoma a. p53 positive nuclei can be seen in
the tumour cells. b, Intracytoplasmic laminin immunoreactivity is
present in the cytoplasm of the tumour cells (Immunoperoxidase
stain, a x 260, b x 510).
evolution of tumours of higher grade and occur in a prein-
vasive stage of the neoplastic epithelium.
According to the literature, positive p53 immunochemistry
may be linked to several situations. It is well-documented
that many mutations lead to an increased half-life of the p53
protein (Bartek et al., 1990; Iggo et al., 1990; Rodriques et
al., 1990). Thus, in many cases there has been a good cor-
relation between mutational analysis and positive immuno-
histochemistry (Bartek et al., 1991; Bennett et al., 1992;
Vahakangas et al., 1992). The half-life of p53 can also in-
crease due to binding to some viral proteins as well as to the
product of the mdm2 gene, which is often amplified in sar-
comas (Vogelstein & Kinzler, 1992). Finally, mutated p53
may bind to wild type p53 and change it to the mutated
conformation (Hainaut & Milner, 1992). Since conformation
and oligomerisation of p53 is putatively important for the
function, the function is probably changed in these cases as
well (Vogelstein & Kinzler, 1992). This means that, whether
due to mutation or other events, accumulation of the protein
probably indicates a change of the state of the cell, as
indicated by a non-mutated, but abundantly present p53
protein in a cancer family (Barnes et al., 1992). Indeed, p53
immunohistochemistry has been suggested as an aid in diag-
nosis of malignancy (Hall et al., 1991) and our current and
earlier studies (Soini et al., 1992) which show more positive
cases among more aggressive tumours as well as other studies
from the literature (Olumi et al., 1990; Sidransky et al., 1991)
are in line with this suggestion.
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Even though p53 immunoreactivity was mostly concentrat-
ed in grade II-III tumours there was, however, one p53
positive grade I tumour, and one p53 positive dysplastic
lesion in which no associated carcinoma was found. If these
cases harbour a mutated p53 protein it is possible that p53
mutations in this material are heterogenous in their nature
and that corresponding proteins have behaved differentially.
It has been shown that different mutant alleles have distinct
biological properties in experimental systems (Levine, 1992).
On the other hand, a p53 event may be an early change in
tumours and take part in the transformation of the tumour
to a more malignant type. However, the only dysplastic
lesion preceding carcinoma (case 3) was p53 positive but the
tumour was negative. The low percentage of positive cells in
this case (up to 5%) may indicate a wild type rather than
mutated p53 (Lu et al., 1992).
Administration of N-butyl-N-(4-hydroxybutyl)nitrosamine
to mice causes changes from dysplasia to invasive carcinoma
in a dose-dependent way suggesting that evolution of car-
cinoma in the bladder is a sequential process through these
stages (Ohtani et al., 1986). However, dysplasia of the blad-
der epithelium in man is often detected in association with
rather than preceeding a carcinoma (Murphy, 1989). As in
our study, such dysplasia is frequently associated with
invasive and aggressive types of transitional cell carcinoma,
and dysplastic lesion in bladders treated for carcinoma may
predict a recurrence of the disease (Murphy, 1989; Wolf et
al., 1985; Kakizoe et al., 1985). The close association
reported here between expression of p53 protein in dysplasia
and the related transitional cell carcinomas suggests that
these processes may be linked together in mechanism. In an
analogous situation in the bronchus, preinvasive and micro-
invasive lesions adjacent to an invasive squamous cell car-
cinoma all contained the same p53 mutations (Viihakangas et
al., 1992). Whether individual cases share similar mutations
of the p53 gene in bladder carcinomas and dysplastic lesions
remains to be determined.
Our findings of the immunohistochemical distribution of
BMs and intracytoplastic laminin immunoreactivity in transi-
tional cell carcinomas are in accordance with the general
observation in other types of tumours (Martinez-Hernandez
& Amenta, 1983; Bosman et al., 1985); the more malignant
and aggressive the tumour is, the more usual is also the
disruption of BMs around the tumour islands and intra-
cytoplasmic laminin immunoreactivity of tumour cells. It has
also been shown that BM disruption in bladder carcinomas
correlates with lower 5-year survival rate, higher tumour
stage, higher histological grade and tumour ploidy (Schapers
et al., 1990). In this material BM disruption was also
associated with positive p53 immunohistochemistry, further
emphasising the fact that p53 positive bladder carcinomas are
of a more aggressive nature. The increased intracytoplasmic
laminin immunoreactivity in high grade tumours reflects the
increased synthesis of BM proteins due to the disruption of
the BMs.
Carcinogenesis is a multistage process in which accumula-
tion of chromosomal changes eventually leads to a develop-
ment of a malignant tumour (Fearon & Vogelstein, 1990). In
addition to p53 gene changes, several other genetic changes,
such as deletion of chromosomes 9 and 11 (Olumi et al.,
1990; Sidransky et al., 1991), activation of ras and c-erbB-2
(Santos et al., 1982; Wright et al., 1991) and inactivation of
the retinoblastoma gene (Ishikawa et al., 1991), have been
observed in bladder carcinomas. Thus a p53 mutation, even
though present in a large number of transitional cell car-
cinomas, represents only one event in the putative pathway
of evolution of these tumours. Because p53 mutations are not
found in all tumours (Sidransky et al., 1991), other pathways
must exist, not requiring p53 mutations at all.
In conclusion, our results show that p53 protein expression
can frequently be found in dysplastic lesions following the
treatment of bladder carcinoma. Since they are associated
with aggressive and recurrent tumours which also harbour a
high rate of p53 protein expression, p53 gene mutations
possibly play a role in the evolution of tumours of a higher
grade. It may be possible to use p53 protein immunohisto-
chemistry as an adjunct in the assessment and follow-up of
epithelial changes in patients with urothelial carcinoma.
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